Mohammed bin Rashid’s AED 8.8m SMA case puts rare-disease funding back on UAE agenda

Sheikh Mohammed bin Rashid Al Maktoum will cover about AED 8.8 million in treatment costs for Katia Abu Al Saud, a 16-month-old Jordanian child with spinal muscular atrophy, according to Emirates 24|7 and Jordanian media reports on 21 August 2026.

The case matters most to CFOs, paediatric operators and insurers because it shows the financial gap around one-off gene therapies. The reported intervention is Zolgensma, a gene therapy for spinal muscular atrophy, with an international price commonly reported at about $2.1 million to $2.4 million. For UAE patients, the practical question is how quickly a child can move from diagnosis to eligibility review, payer approval, philanthropic funding or cross-border referral.

What happened in Dubai

Emirates 24|7 said Jordanian media highlighted Sheikh Mohammed’s initiative after the child’s mother appealed for help. The family said the treatment was unavailable in Jordan and that doctors advised follow-up in Dubai at Al Jalila Children’s Hospital. The National reported that Katia is expected to receive treatment in Dubai and that the family would travel from Jordan to the UAE.

Spinal muscular atrophy is a rare inherited neuromuscular disease. Zolgensma is designed as a one-time gene therapy that replaces the faulty SMN1 gene. Eligibility is time-sensitive because many treatment protocols focus on very young children, often before the age of two, and require specialist genetic, neurological and cardiac assessment before administration.

For Dubai providers, the regulatory reference point is the Dubai Health Authority (DHA), which licenses healthcare facilities and professionals outside special zones and maintains the Dubai Medical Registry. In Abu Dhabi and Al Ain, the equivalent regulator is the Department of Health Abu Dhabi (DOH). In the northern emirates, operators should check Ministry of Health and Prevention (MOHAP) and Emirates Health Services licensing routes.

What clinics and insurers should check

The immediate lesson is operational. A child with suspected spinal muscular atrophy needs a pathway that covers diagnosis, clinical eligibility, payer review and referral within weeks, not months. Delays can change the clinical value of therapy and the payer’s assessment of medical necessity.

• For paediatric clinics: document referral protocols for hypotonia, delayed motor milestones and feeding or respiratory weakness in infants.
• For hospitals: confirm whether genetic testing, paediatric neurology, intensive care backup and pharmacy governance are available in-house or through a referral partner.
• For insurers: define the evidence required for exceptional approval, including genetic confirmation, specialist reports and age or weight criteria.
• For patients: request written eligibility criteria and a named case manager before starting any overseas or charitable funding process.

UAE insurers such as Daman, Thiqa and Sukoon publish different benefit structures by policy, network and emirate. Families and providers should verify coverage against the member’s specific policy document and obtain written pre-authorisation before assuming that a high-cost medicine, imported therapy or hospital administration fee is covered.

The funding signal for UAE operators

The case is also a market signal. Dubai has specialist paediatric infrastructure capable of receiving regional rare-disease referrals, but the payment model for therapies above AED 1 million remains fragmented. Hospital finance teams need a separate pathway for ultra-high-cost drugs, because standard inpatient approval workflows were built for shorter admissions, surgery packages and recurring medicines.

For CFOs, the risk is receivables exposure. A therapy priced near AED 8.8 million cannot be treated as a routine pharmacy item. Hospitals should require documented payer approval, philanthropic commitment or self-pay escrow before procurement. For COOs, the risk is coordination failure between genetic testing, pharmacy importation, cold-chain handling and paediatric intensive care readiness. For CMOs, the case will increase parent demand for clear information on rare-disease screening and specialist access.

There is no single public UAE tariff for Zolgensma administration that operators can use as a benchmark. The reliable route is to request a written estimate from the treating hospital, split by medicine cost, admission, diagnostics, physician fees, intensive care standby and follow-up. For imported therapies, hospitals should also state expected procurement timelines and refund terms if eligibility changes.

The next watch point is whether rare-disease funding becomes more structured across Dubai, Abu Dhabi and the northern emirates. Until then, providers should keep a named escalation route for exceptional paediatric cases and maintain current listings in licensed directories. Patients and referring clinics can start with the UAE Open Healthcare Directory to find licensed pediatrics providers and verify local access points before making referral decisions.